- The financing will support development of a commercial instrument system based on the company’s proprietary and disruptive MAGNA™ technology.
- MAGNA™ is set to unlock the field of dynamic genomics.
- Funds raised from a global investor syndicate led by Lansdowne Partners and Bpifrance and supported by funds bringing additional experience in the life science sector.
Paris, France and Cambridge, UK, 15 December 2021: Depixus®, a biotechnology company developing a unique technology for the fast, accurate, and straightforward extraction of multiomic information from DNA, RNA, and proteins, today announces it has raised EUR 30.6 million in an oversubscribed Series A financing. The funds will be used to further develop its proprietary MAGNA™ instrument system, workflows, and reagents towards commercial launch. The round was co-led by Lansdowne Partners and the PSIM Fund operated by Bpifrance on behalf of the French State, with participation by Casdin Capital, and existing investors, including Arix Bioscience. This financing brings the company’s total equity and grant funding to-date to over EUR 41 million (USD 47 million).